RecruitingNot ApplicableNCT06882356

The Glaucoma and Retinopathy Screening Study

The Glaucoma and Retinopathy Screening Study (GRaSS)

Sponsor

Massachusetts Eye and Ear Infirmary

Enrollment

2,000 participants

Start Date

Jul 16, 2025

Study Type

INTERVENTIONAL

Conditions

Glaucoma

Summary

The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This trial studies whether an AI-based eye screening tool used for diabetic retinopathy can also help detect glaucoma at the same time in people with diabetes. You may be eligible if... - You have diabetes and are already undergoing AI-based diabetic retinopathy screening using the LumineticsCore system at a primary care center - You are able and willing to provide informed consent to participate You may NOT be eligible if... - You are not currently undergoing AI-based retinopathy screening at a participating primary care center - You are unwilling or unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.